Research programme: glaucoma therapeutics - SALVAT

Drug Profile

Research programme: glaucoma therapeutics - SALVAT

Latest Information Update: 07 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SALVAT
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma

Most Recent Events

  • 15 Nov 2016 iCo Therapeutics enters into a exclusive option rights with Laboratorios SALVAT for a novel glaucoma asset
  • 15 Nov 2016 Laboratorios SALVAT has patent protection for glaucoma drug
  • 15 Nov 2016 Preclinical trials in Glaucoma in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top